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The balance between osteoblast and osteoclast 
activation  and  function  is  critical  for  bone   
homeostasis.  Osteoblasts,  which  are  cells  of 
mesenchymal origin, secrete bone-matrix pro-
teins to promote mineralization; whereas macro-
phages,  neutrophils,  and  osteoclasts,  which 
are derived from a common hematopoietic 
precursor, are key contributors to the patho-
genesis in bone resorptive disorders such as 
rheumatoid  arthritis  (RA).  During  autoim-
mune  joint  disease  the  excessive  influx  of   
inflammatory macrophages and granulocytes 
leads to an increased development and activa-
tion of osteoclasts. The inflammatory response 
promotes tissue injury and osteoclast activation, 
which leads to detrimental cartilage and bone loss. 
The primary signals for this process are induced 
in the presence of M-CSF by receptor activa-
tor of NF-B ligand (RANKL), which in turn 
activates the TRAF6, c-Fos, and the NFATc1 
pathway  (Ishida  et  al.,  2002;  Takayanagi, 
2002, 2005a). Additional co-stimulatory signals 
derived  from  immunoreceptor  tyrosine-based 
activation  motif  (ITAM)–containing  mole-
cules are  also  essential  for  osteoclastogenesis 
(Koga et al., 2004). DNAX adaptor protein 12 
(DAP12) is a trans-membrane adaptor mole-
cule  that  transduces  activating  signals  via 
ITAM for a range of cell surface receptors   
on  NK  cells,  granulocytes,  and  macrophages 
(Lanier et al., 1998; Kaifu et al., 2003). There 
are  many  known  DAP12  pairing  partners, 
including myeloid DAP12-associating lectin-1 
(MDL-1), which has been shown to regulate 
myeloid cell–associated inflammatory responses 
(Bakker et al., 1999; Aoki et al., 2004; Chen 
et al., 2008). MDL-1—a C-type lectin do-
main  family  5,  member  A  (CLEC5A)—is 
highly expressed on TNF-activated macro-
phages (Bakker et al., 1999). Cross-linking cell 
surface  MDL-1  receptors  induces  DAP12-
ITAM–dependent calcium mobilization (Bakker 
et al., 1999) and activation of the Syk and   
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DNAX adaptor protein 12 (DAP12) is a trans-membrane adaptor molecule that transduces 
activating signals in NK and myeloid cells. Absence of functional Dap12 results in osteo-
clast defects and bone abnormalities. Because DAP12 has no extracelluar binding domains, 
it must pair with cell surface receptors for signal transduction. There are at least 15 known 
DAP12-associating cell surface receptors with distinct temporal and cell type–specific 
expression patterns. Our aim was to determine which receptors may be important in 
DAP12-associated bone pathologies. Here, we identify myeloid DAP12-associating lectin 
(MDL)-1 receptor (also known as CLEC5A) as a key regulator of synovial injury and bone 
erosion during autoimmune joint inflammation. Activation of MDL-1 leads to enhanced 
recruitment of inflammatory macrophages and neutrophils to the joint and promotes bone 
erosion. Functional blockade of MDL-1 receptor via Mdl1 deletion or treatment with  
MDL-1-Ig fusion protein reduces the clinical signs of autoimmune joint inflammation. 
These findings suggest that MDL-1 receptor may be a therapeutic target for treatment of 
immune-mediated skeletal disorders.
© 2010 Joyce-Shaikh et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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MDL-1 receptor activation enhances inflammatory cell 
infiltration, cartilage damage, and bone erosion
The Mdl1 mRNA expression in bone marrow and synovium 
prompted us to determine which cell types might express this 
immune  regulator  in  human  RA  tissue.  We  found  that   
MDL-1 is highly expressed on myeloid cells in the inflamed 
pannus. We also observed the same expression pattern in 
mouse  inflamed  joint  (not  depicted).  The  expression  of 
MDL-1 appears to colocalize with a subset of CD68+ inflam-
matory macrophages, as indicated by the immunostaining of 
serial sections from synovial RA samples (Fig. S2). To con-
firm colocalization of MDL-1 with myeloid cells in inflamed 
pannus,  we  performed  immunofluorescent  staining  with 
anti–MDL-1 (phycoerythrin) and CD11b (FITC). Interest-
ingly, most, but not all, of the CD11b+ cells also coexpress 
MDL-1 as shown in the merged immunofluorescent images, 
which appeared yellow (Fig. S2).
Given the expression pattern of MDL-1 in joint tissues, 
we examined its expression on leukocytes during a collagen 
antibody-induced arthritis (CAIA) model. This disease is 
  induced by passive transfer of type II collagen-specific anti-
bodies and requires direct myeloid cell activation to promote 
pathology. We found that CD11b+ Ly6G+ MDL-1+ cells   
increased from 35 to 50% in the bone marrow 7 d after ar-
thritis induction. Similarly, MDL-1+ cells in peripheral blood 
increased  from  25%  in  controls  to  40%  in  arthritic  mice   
(Fig. S3). We next determined the function of MDL-1 in 
CAIA  using  anti–MDL-1  agonist  mAbs  that  specifically 
cross-link and activate the MDL-1 receptor pathway. Mice 
given anti–MDL-1 agonists in conjunction with the arthro-
genic antibody cocktail exhibit increased disease incidence 
and severity (Fig. 2 A). Anti–MDL-1 treatment promoted an 
increase in the total number of bone marrow CD11b+ Ly6G+ 
granulocytes and CD11b+ Ly6G monocytes compared with 
isotype-treated controls (Fig. 2 B). This increase correlated 
with higher levels of total MPO activity in the bone marrow 
(not depicted) and elevated circulating peroxidase-positive 
(%HPX) neutrophils and monocytes (Fig. 2 C and not   
depicted),  indicating  that  activation  of  MDL-1  promoted 
  expansion of “reactive” myeloid cells capable of inducing   
tissue damage. As early as 1 d after disease onset, anti–MDL-1 
agonist-treated mice already showed greater clinical scores 
compared with the isotype control group. By day 4, histopa-
thology shows a dramatic increase in neutrophil infiltration 
into the arthritic paws of anti–MDL-1–treated mice (>60% 
PMNs) compared with isotype-treated controls (20% PMNs), 
which  corresponds  with  intense  cartilage  damage,  bone   
erosion, and pannus tissue formation (Fig. 2, D and E). By 
day 11, the extent of damage in the anti–MDL-1 treatment 
group is remarkable, with near maximum pathology scores 
for inflammatory cell infiltrate, articular cartilage destruction, 
and almost complete cortical bone erosion of the metatarsal-
phalange joints. To assess the roles of granulocytes/mono-
cytes in this MDL-1–driven disease, mice were given anti-GR1 
mAb, which depletes Ly6G+ granulocytes and a subset of 
Ly6G+/Ly6C+ monocytes. In vivo depletion was confirmed 
phospholipase C signaling pathways (Lanier et al., 1998; 
Mao et al., 2006). The ITAM-dependent calcium signaling 
pathway is a critical “co-stimulatory” signal for RANKL-
dependent regulation of bone remodeling and homeostasis 
(Takayanagi, 2005a).
Although  MDL-1  expression  is  up-regulated  in  acti-
vated myeloid cells, it is not known whether this receptor 
plays  any  role  in  autoimmune  inflammation.  Given  the   
fact that MDL-1’s pairing partner, DAP12, has a role in 
osteoclast  formation  and  bone  remodeling  (Humphrey   
et al., 2004, 2006; Kaifu et al., 2003), we tested whether 
MDL-1 activation could affect autoimmune arthritis. In 
this study, we demonstrate that MDL-1 is expressed on 
inflammatory  macrophages  and  neutrophils,  as  well  as 
bone  marrow–derived  osteoclast  precursors.  Activation   
of  the  MDL-1  receptor  during  joint  inflammation  en-
hances myeloid cell infiltration and promotes IL-1, IL-6, 
IL-17A, and TNF expression, resulting in severe cartilage 
damage and bone erosion. In contrast, neutralization of 
MDL-1 function down-regulates TRAP, cathepsin K, and   
MMP9 expression, subsequently preserving bone mineral 
density.  These  results  suggest  that  therapeutic  targeting   
of the MDL-1 receptor may suppress inflammation and, 
  ultimately,  bone  resorptive  pathways  during  inflamma-
tory conditions.
RESULTS
MDL-1 receptor is expressed on bone marrow cells  
and inflamed joints
In a tissue array gene expression analysis of MDL-1 receptor, 
we found that human (Fig. 1 A) and mouse (Fig. 1 B) bone 
marrow  cells  and  joint  tissues  express  the  highest  levels   
of  Mdl1.  Correspondingly,  MDL-1  protein  is  expressed   
on murine granulocytes (CD11b+ Ly6G+) and monocytes 
(CD11b+ Ly6G) from bone marrow and the peripheral 
blood (Fig. 1 C). We observed that activation with TNF, but 
not  IFN-,  further  enhances  Mdl1  mRNA  and  protein 
  expression  in  bone  marrow–derived  macrophage  colony-
stimulating factor (MCSF)-dependent macrophages (Fig. 1 D). 
To assess whether triggering the MDL-1 receptor could acti-
vate myeloid cells, we generated mAbs that are capable of 
cross-linking and promoting MDL-1 activation. To test the   
antibody specificity and function, we performed a bioassay 
where cellular degranulation can be triggered by MDL-1/
DAP12 phosphorylation (see Materials and methods). Treat-
ment of an MDL-1/DAP12-transfected mast cell line with 
an anti–MDL-1 mAb (clone DX163) induces specific de-
granulation, demonstrating that clone DX163 is an agonistic 
mAb that activates the MDL-1–DAP12 signaling pathway 
(Fig.  S1).  We  next  confirmed  the  activities  of  the  anti– 
MDL-1 mAb in primary cells. Wild-type, but not Dap12/, 
macrophages produced inflammatory mediators in response 
to  anti–MDL-1  treatment.  TNF,  G-CSF,  IL-1,  and   
MCP-1 (Fig. 1 E and not depicted) were up-regulated by 
anti–MDL-1 antibodies, and this was further enhanced in the 
presence of LPS, a TLR-4 agonist.JEM VOL. 207, March 15, 2010 
Article
581
Absence of MDL-1 receptor inhibits joint inflammation  
and preserves bone density
Based on the association of DAP12 and MDL-1 with joint 
diseases, we determined if blockade of this innate inflamma-
tory pathway could attenuate myeloid cell–mediated joint 
inflammation and bone erosion. Mice were generated in 
which all six exons of Mdl1 were deleted via homologous re-
combination using C57BL/6 embryonic stem cells (Fig. S6). 
Successful deletion of Mdl1 was confirmed by PCR and flow 
cytometry. Mdl1/ mice are viable and born in the expected 
Mendelian ratios. The number of myeloid and lymphoid cell 
subsets is similar in Mdl1/ and wild-type mice (unpublished 
data). CAIA disease incidence and severity of both Dap12/ 
and  Mdl1/  are  reduced  compared  with  wild-type  mice 
(Fig. 3 A). In addition, analysis of proinflammatory cytokines 
by flow cytometry shown in Fig. S4. Mice given anti-GR1 
treatment  1  d  before  induction  of  MDL-1–driven  CAIA 
showed significant disease amelioration, indicating that GR1-
positive myeloid cells play an important role in promoting 
MDL-1–activated joint inflammation (Fig. 2 F).
We also assessed the role of MDL-1 receptor in collagen-
induced arthritis (CIA), which is a T, B, and myeloid cell–
dependent model of arthritis. Mice were immunized with 
type II collagen and treated with anti–MDL-1 agonist mAb 
on the day of clinical disease onset (day 18 after collagen im-
munization). 2 d after MDL-1 activation, we already noticed 
enhanced joint swelling response. The disease quickly pro-
gressed to a very severe form of arthritis (Fig. S5). These re-
sults prompted us to investigate whether specific blockade of 
MDL-1 could inhibit inflammatory joint disease.
Figure 1.  Regulation of MDL-1 receptor expression. (A and B) Bone marrow cells and joint tissues show the highest level of MDL-1  
expression. Quantitative PCR analysis of human (A) and mouse (B) anatomy panels generated from pooled tissue samples from at least five donors.  
(C) MDL-1 is expressed on murine granulocytes (CD11b + Ly6G high) and monocytes (CD11b + Ly6G low) from bone marrow and peripheral blood. Histo-
grams in gray color are rIgG2a isotype staining controls. Data are representative of three experiments. (D) TNF but not IFN- promotes MDL-1 expression. 
Murine bone marrow cells were cultured with MCSF in the presence of IFN- or TNF and mRNA was isolated for MDL-1 expression analysis by Q-PCR. Cell 
surface expression of MDL-1 was determined by flow cytometry. Data representative of at least three separate experiments with similar results. (E) Anti–
MDL-1 activates bone marrow–derived macrophages to produce TNF and G-CSF. Bone marrow cells isolated from three mice were cultured with indicated 
antibodies and/or LPS for 36 h. Culture supernatants were assayed for secreted cytokines by Luminex assay. * indicates significance (P < 0.01) as deter-
mined by Student’s t test. Results are representative of three separate experiments with similar results.582 MDL-1 regulation of joint inflammation | Joyce-Shaikh et al.
inhibit the in vivo activities of MDL-1. This soluble MDL-1 
antagonist is composed of a murine FcRI binding-deficient 
mutant IgG2a covalently linked to the extracellular portion 
of MDL-1 (MDL-1–Ig fusion protein). MDL-1–Ig fusion–
treated mice were highly resistant to both CIA and CAIA 
compared with controls (Fig. 3, C and D). In the CIA study, 
the MDL-1–Ig-fusion treatment was initiated at day 18 when 
and osteoclast markers in arthritic paws show a protective   
effect of deleting Mdl1 and Dap12 (Fig. 3 B). The absolute   
values of these inflammatory genes in arthritic and naive   
control paws are shown in Fig. S7.
Because the endogenous ligand for the MDL-1 receptor 
has not been identified, we generated a soluble MDL-1 mol-
ecule, which would be expected to engage the ligand and   
Figure 2.  MDL-1 activation enhances autoimmune arthritis. (A) Treatment with anti–MDL-1 agonist mAb exacerbates CAIA. B10RIII mice (n =  
5/group) were given arthrogen to induce arthritis. Mice treated with anti–MDL-1 mAb (clone DX163) at the time of arthrogen treatment showed disease 
exacerbation compared with isotype controls. Maximum clinical score of individual mice from two separate anti–MDL-1 treatment studies is shown on 
the right. Results are representative of at least four experiments. (B) Anti–MDL-1 treatment increases the absolute number of bone marrow granulocytes 
and monocytes. Each data point is FACS analysis of cells extracted from two tibias. (C) Peripheral blood peroxidase-positive neutrophils and macrophages 
are elevated in anti–MDL-1 treated mice, as shown by ADVIA analysis. The studies in B and C were performed twice. (D) Representative H&E-stained  
micrographs of metatarsal-phalange joints from the study shown in A. Bars: (top left, bottom left, and top right) 200 µm; (bottom right) 60 µm. The anti–
MDL-1 agonist treatment group showed intense neutrophil and macrophage infiltration, as well as pannus tissue formation with extensive bone erosion. 
(E) Histopathology was performed in a masked fashion. Leukocyte infiltration and percentage of PMN infiltration were determined in the synovium and 
joint space. Percent PMNs: 1 = <20%, 2 = 20–40%, 3 = 40–60%, and 4 = >60%. Pannus tissue formation, cartilage destruction, and cortical bone ero-
sions were assessed as described in the Materials and methods section. The severity was graded on a scale of 0–4. Comparisons between anti–MDL-1 and 
isotype control were determined using the Mann Whitney U test. * indicates P < 0.05 and is considered statistically significant. (F) Depletion of granulo-
cytes/monocytes reduced anti–MDL-1–driven CAIA. Date shown are summary of two separate experiments (n = 10 per treatment group). Disease was 
induced as in A with additional groups that were pretreated on day 1 with anti-GR1 mAb (clone RB6-8C5, rIgG2a isotype) that depletes Ly6G+ and a 
subset of Ly6C+ cells. Disease was induced on day 0 and mice were given anti–MDL-1 mAb (clone DX163) or an IgG1 isotype control. Depletion of GR1+ 
populations was confirmed by flow cytometry (Fig. S4).JEM VOL. 207, March 15, 2010 
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We confirmed the histopathology findings and quantified 
the  magnitude  of  bone  destruction  using  x-ray  microCT 
analysis. The bone mineral density and the bone structural 
changes of articular phalangeal joints were assessed at day 11 
after CAIA induction. Fig. 4 A shows high resolution three 
dimensional rendering of microCT scans of hind paws. Anti–
MDL-1 agonist treatment induces considerable cortical bone 
destruction,  whereas  MDL-1–Ig  fusion  protein—which 
functions as an effective antagonist—dramatically blocks bone 
erosion. Although histopathology findings show intense cor-
tical bone erosion at the joint space of anti–MDL-1–treated 
40% of the mice (n = 29 from 2 studies) already showed initial 
clinical signs of disease. Strikingly, only a few days after 
MDL-1–Ig treatment, the arthritic mice already demon-
strated clinical improvement. This contrasts with the rapid dis-
ease progression observed in isotype controls and anti–MDL-1 
agonist–treated mice (Fig. 3 C). In CAIA studies, MDL-1–Ig 
treatment also displays similar protection from disease (Fig. 3 D). 
Histopathological assessment of hind paws showed the isotype 
control group have mild cellular infiltrate and bone erosion, 
whereas  mice  treated  with  the  MDL-1–Ig  fusion  protein 
have little or no pathological signs of disease (Fig. S8).
Figure 3.  MDL-1 blockade inhibits autoimmune arthritis. (A) C57BL/6 control, Dap12/, and Mdl1/ mice were injected with arthrogenic mAbs 
to induce CAIA. Mean clinical scores (n = 5/group) ± SEM are shown. Result is representative of two studies. * indicates statistical significance. (B) Hind 
paw mRNA from A was isolated for gene expression analysis. The absolute values of the inflammatory genes are shown in Fig. S7. (C) MDL-1 activation 
enhanced T cell– and myeloid cell–dependent arthritis. B10RIII mice were immunized with bovine type II collagen emulsified in CFA at day 0 to induce 
collagen-induced arthritis. Anti–MDL-1 agonist (clone DX163) was given on day 18 of immunization. Statistical significance was determined by analysis 
of variance (ANOVA). Results are representative of two studies. (D) B10RIII mice (n > 5/group) were given 1.5 mg of Arthrogen to induce CAIA. MDL-1 Ig 
fusion protein or control proteins were administrated at the time of Arthrogen treatment. * indicates statistical significance (P < 0.001) as determined by 
ANOVA analysis.584 MDL-1 regulation of joint inflammation | Joyce-Shaikh et al.
dataset into a two dimensional picture and is consistent with 
previously  published  MicroCT  results  in  mouse  arthritis 
models (Barck et al., 2004). To quantify the extent of the 
bone destruction, we performed histomorphometric analysis 
of cortical bones and determined that MDL-1 agonist mAb-
treated mice show substantial loss of bone volume, bone den-
sity,  and  cortical  thickness  compared  with  the  moderate 
changes  in  the  Ig  control  groups  (Fig.  4  B).  In  contrast, 
MDL-1–Ig fusion–treated mice have bone integrity, density, 
volume, and bone mass values that are nearly comparable to 
healthy naive mice, confirming that blocking MDL-1 recep-
tor activation maintains joint integrity. It has been shown 
that circulating levels of TRAP 5b are proportional to the 
number of osteoclasts (Scarnecchia et al., 1991; Henriksen   
et al., 2007). By testing serum samples during the course of 
disease, we found that the osteoclast-specific TRAP 5b levels 
were significantly increased after MDL-1 receptor activation 
(Fig. 4 C). The elevated TRAP 5b levels correlate with the 
enhanced  bone  erosion  in  the  anti–MDL-1–treated  mice. 
RANKL levels are also increased in anti–MDL-1 agonist–
treated mice, whereas MDL-1-Ig fusion–treated mice have 
levels comparable to naive animals.
MDL-1 signaling regulates osteoclast function
To investigate the immune responses regulated by MDL-1 
activation,  we  assessed  the  expression  of  proinflammatory   
cytokines, osteoclast markers, and myeloid cell markers in   
arthritic paws. On day 4 after induction of CAIA, which is 
just before the peak of paw swelling response in the control 
groups, proinflammatory genes including IL-1, IL-6, and 
IL-17 are suppressed in MDL-1–Ig fusion protein–treated 
mice, whereas the anti–MDL-1–treated group show en-
hanced cytokine gene expression (Fig. 5 A). Importantly, 
genes  associated  with  bone  destruction  such  as  RANKL, 
MMP9, ATPV0D2, and TRAP are down-regulated in paws 
after MDL-1–Ig fusion treatment and up-regulated in anti–
MDL-1 agonist treatment. Also, myeloid cell–specific genes 
including CD11b, RANK, and DAP12 are reduced in the 
MDL-1–Ig fusion group and elevated in anti–MDL-1 agonist 
group.  In  addition,  CXCL1,  which  promotes  neutrophil   
recruitment, is also up-regulated by the MDL-1 agonist. We 
also determined the gene expression of arthritic paws at day 
11 and found similar patterns (unpublished data). Interest-
ingly, even through MDL-1 activation enhanced TNF, IL-6, 
RANK, and TRAP expression, both type I and II IFNs were 
undetectable in the inflamed paws (the Q-PCR cycle thresh-
old is 40), consistent with the concept that MDL-1 is linked 
with the TNF–RANKL pathway rather than the IFN–STAT1 
pathway that inhibits bone resorption mechanisms.
The apparent regulation of the TRAP, RANKL, AT-
PV0D2, and MMP9 expression after anti–MDL-1 treatment 
suggests MDL-1 receptor activation may promote osteoclast 
development and function. To test this, we treated wild-type 
bone marrow cells with an anti–MDL-1 agonist in the pres-
ence of RANKL (10 ng/ml). MDL-1 activation increases the 
kinetics of cell fusion, resulting in greater size and frequency 
mice, the microCT three dimensional image reconstruction 
produced  images  suggestive  of  metaphyseal  damage.  This 
may be because if the rendering of a three dimensional   
Figure 4.  MDL-1 blockade inhibits bone erosion and inflamma-
tion. (A) Hind paws from mice in Fig. 3D were harvested on day 11 and 
prepared for MicroCT analysis. Images show high resolution three-
  dimensional rendering of MicroCT scans. MDL-1 Ig-fusion protein  
(antagonist)–treated mice show no sign of cortical bone destruction, 
whereas the agonist MDL-1 antibody (clone: DX163) treated mice show 
greater bone destruction than control IgG1-treated mice. Results are 
representative of three separate experiments. (B) Quantification of bone 
integrity indicates increased bone loss in anti–MDL-1 agonist-treated 
mice. Comparable regions of interest (ROI) consisting of three metatarsal 
joints from each mouse were selected for analysis. Bone volume (BV), 
bone mass (BM), bone mineral density (BMD = BM/BV mg/cm3), and mean 
cortical thickness (mm) were quantified from MicroCT scans using GE 
MicroView software v2.2. Student’s t test was used to determine signifi-
cance where ***, P < 0.001; **, P < 0.01; *, P < 0.05. (C) ELISA quantification 
of Serum TRAP 5b and RANKL. Day 20 serum levels of TRAP5b and RANKL 
from individual mice are shown. TRAP5b levels from day 11 also show 
similar results. * indicates P < 0.05 by Student’s t test analysis.JEM VOL. 207, March 15, 2010 
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Figure 5.  MDL-1 activation promotes NFATc1 nuclear translocation and enhances osteoclast formation. (A) Gene expression of pooled (n = 3) 
hind paws treated as in Fig. 3D were harvested at day 4 and prepared for Q-PCR analysis. Data are representative of four experiments. (B) Bone marrow 
cells were cultured in plastic dishes in the presence of 10 ng/ml RANKL and MCSF. Anti–MDL-1, but not isotype control (or medium control; not depicted) 
increased the number multinuclear cells (left) and osteoclast size (right). Data are representative of at least four separate experiments. Bars, 200 µm.  
(C) MDL-1 regulates NFATc1 nuclear expression. C57BL/6 bone marrow cells were cultured with indicated growth factors and antibodies. Cells were  
cultured for 6 d and nuclear lysates prepared for Active Motif Nuclear NFATc1 colorimetric assay. Nuclear NFATc1 was detected by a plate-bound NFAT 
oligonucleotide consensus sequence (5-AGGAAA-3), a primary NFATc1-specific antibody, and a secondary HRP-conjugated mAb. Results are representative 
of two studies. * indicates significance (P < 0.01) as determine by ANOVA analysis.
of mature osteoclasts (Fig. 5 B). These results suggest MDL-1 
activation  promotes  in  vitro  osteoclastogenesis  and  cell   
fusion. TRAP and cathepsin K are osteoclast-specific genes 
regulated by the NFATc1 transcription factor (Matsumoto   
et  al.,  2004;  Takayanagi,  2005a).  To  determine  whether 
MDL-1 directly regulates NFATc1, anti–MDL-1–activated 
bone marrow cells were prepared for NFATc1 nuclear lysate 
ELISA. MDL-1 + RANKL induced a significant increase of 
phospho-NFATc1 nuclear localization over RANKL alone, 
indicating that MDL-1-DAP12–mediated signaling promotes 
amplification of this transcription regulator required for   
osteoclast differentiation (Fig. 5 C). These in vitro osteoclast 586 MDL-1 regulation of joint inflammation | Joyce-Shaikh et al.
the relative contribution of MDL-1 and DAP12 in bone 
homeostasis.
Although  the  endogenous  ligands  for  the  MDL-1   
receptor have not been identified, a recent study has dem-
onstrated that the dengue virus capsid protein activates the 
MDL-1–DAP12–ITAM  pathways  leading  to  intense   
immune  pathologies  during  the  viral  infection  (Chen   
et al., 2008). The hallmarks of dengue “break-bone” fever 
are cytokine storm, vascular leakage, and severe joint pain 
(Mathew and Rothman, 2008). Intriguingly, in a mouse 
model of dengue hemorrhagic disease, specific blockade   
of  MDL-1  receptor  inhibited  the  cytokine  storm  and   
vascular leakage. This tissue damage is associated with ex-
cessive IL-6, TNF, and MIP-1a production without af-
fecting  IFN-  production  (Chen  et  al.,  2008).  This  is 
consistent  with  our  observation  that  MDL-1  activation   
induced TNF, IL-1, IL-6, (which is linked with NF-B, 
TRAF6,  and  STAT3  activation)  but  not  IFN-  and   
IFN-  (STAT1  activation).  Resent  studies  have  shown 
that  both  type  I  and  II  IFNs  have  profound  STAT1-
  dependent inhibitory effects on immune-mediated arthri-
tis  and  osteoclast  formation  (Takayanagi  et  al.,  2005b). 
This  is  consistent  with  our  observation  that  MDL-1   
expression on myeloid cells is enhanced by TNF but not 
IFN- (Fig. 1).
A recent study has uncovered the molecular basis for 
TNF-dependent bone resorption versus tissue inflamma-
tion  (Ochi  et  al.,  2007).  TNF  was  shown  to  promote   
bone loss by inducing osteoclast expression of paired Ig-
like receptor A (PIR-A), which partners and signals via 
ITAM-containing  Fc  receptor    (FcR).  This  induced 
accelerated osteoclastogenesis, which correlated with en-
hanced bone destruction and osteoporosis. Interestingly, 
when the PIR-A–FcR pathway was inhibited, TNF still 
promoted soft tissue inflammation, but not bone resorp-
tion. In this study, we show that blocking MDL-1–DAP12 
predominantly reduced tissue inflammation by reducing 
TNF, IL-1, and IL-6 secretion and neutrophil/macro-
phage infiltration. Further studies are required to confirm 
the MDL-1–intrinsic role of osteoclast development and 
bone resorptive function.
It is increasingly evident that merely targeting inflamma-
tion  alone  may  not  be  an  adequate  treatment  for  many   
types of joint disorders because bone resorption is an integral 
part of these diseases. Therefore, new therapeutic strategies 
need to incorporate both antiinflammatory and antiresorptive 
activities. The possibility that MDL-1 may regulate both in-
flammatory and bone resorptive mechanisms makes this a 
promising target for treatment of inflammatory arthritis. We 
have bridged the findings in our mouse studies to human   
diseases  by  demonstrating  human  MDL-1  expression  in   
synovial tissues from RA patients. Further clinical studies are 
needed to confirm a pathogenic role for MDL-1 in human 
skeletal  disorders  and  to  determine  whether  this  DAP12- 
paring  receptor  is  a  therapeutic  target  for  treatment  of   
inflammatory and/or degenerative bone disorders.
functional assays, together with our in vivo observations that 
blockade of MDL-1 function reduces autoimmune joint   
inflammation and bone erosion, suggest that MDL-1 plays a 
critical role in joint diseases.
DISCUSSION
In this study, we have identified MDL-1 receptor as a key 
mediator of autoimmune joint inflammation. It appears that   
MDL-1 activation contributes to two distinct cellular mecha-
nisms of tissue destruction. Not only does MDL-1 activation   
recruit substantial numbers of bone marrow–derived inflam-
matory macrophages and neutrophils, it also promotes osteo-
clast activation. Depletion of circulating granulocytes and/or 
monocytes  significantly  reduces  MDL-1–dependent  joint   
inflammation  during  CAIA,  suggesting  that  inflammatory   
macrophages and neutrophils play a key role in MDL-1–
  mediated  pathology.  Direct  Blockade  of  MDL-1  function 
also down-regulates paw swelling responses and inhibits pan-
nus tissue formation while preserving bone volume and min-
eral density. We also demonstrate that MDL-1 activation 
increases the expression of NFATc1 and ATPV0D2, which 
control cell fusion (Lee et al., 2006), as well as regulating 
bone resorption via TRAP and cathepsin K in osteoclasts 
(Takayanagi, 2005a). These results suggest that targeting the 
MDL-1 pathway may modulate several important biologi-
cal processes that control bone metabolism and inflammatory 
bone disease.
Previous studies have shown that the pairing partner of 
MDL-1  receptor—DAP12  has  important  roles  in  bone   
metabolism. Patients with loss of function mutations in 
DAP12  present  with  polycystic  lipomembranous  osteo-
dysplasia and sclerosing leukoencephalopathy, also known 
as Nasu-Hakola disease. In a linkage disequilibrium analy-
sis, Paloneva et al. (2000) mapped this disease to a 1.8-Mb   
region of chromosome 19Q13.1. Sequencing the candi-
date genes in this region revealed Dap12 to carry several 
disease-associated variants, including a homozygous dele-
tion  encompassing  exons  1–4.  Nasu-Hakola  disease  is 
characterized by lipid-filled bone cysts found in articular 
joints of young adult patients, which leads to bone pain 
and fractures (Mii et al., 1991). These patients also show 
signs of presenile dementia associated with loss of myelin 
in the frontal lobe in addition to the osteoporotic features. 
However, peripheral blood mononuclear cells from the 
Dap12-deficient patients exhibit a delayed differentiation 
of  osteoclasts  with  reduced  bone  resorption  capability 
(Paloneva et al., 2003). The reduced in vitro osteoclast   
activity  does  not  match  the  decreased  trabecular  bone 
density in Dap12-deficient patients (Paloneva et al., 2001). 
In  preliminary  trabecular  bone  measurement  studies,   
we  found  differences  between  Dap12/  and  Mdl1/ 
mice. Consistent with previous studies (Humphrey et al., 
2004,  2006),  Dap12/  mice  show  mild  osteopetrosis. 
Unexpectedly, Mdl1/ mice show a dysregulated bone 
phenotype  with  irregular  trabecular  bone  connectivity 
(unpublished data). Future studies are needed to address JEM VOL. 207, March 15, 2010 
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2, swelling of two or more digits; 3, swelling of the entire paw. The maximal 
clinical score per mouse was 12.
GR-1  depletion  in  antibody-induced  arthritis  (CAIA). 12-wk-old 
B10.RIII mice were dosed s.c. with 0.5 mg of anti-GR1 antibody (clone 
RB6-8C5) or IgG2b isotype control on day 1 before arthritis induction. 
Mice were given two subsequent s.c. doses of anti-GR1 or isotype on day 2 
and 5 after disease induction.
Histopathological assessment. The paws were removed, fixed, decalci-
fied in Cal-EX II (Thermo Fisher Scientific) for 7 d, and embedded in paraf-
fin. Subsequently, the paw sections were stained with hematoxylin and eosin 
and examined by light microscopy. A histological analysis of synovial, bone, 
and cartilage tissues was performed as a blind test. Leukocyte infiltration and 
percentage of PMNs infiltration were determined in the synovium and joint 
space. Pannus tissue formation, cartilage destruction, and cortical bone   
erosions were assessed. The severity was graded on a scale of 0–4. Compari-
sons between groups were assessed with the two-tailed unpaired Student’s   
t test with a P value of <0.05 considered as statistically significant. Calcula-
tions were performed with the statistical package, GraphPad Prism 4 (Graph-
Pad Software, Inc.).
Histopathology scoring criteria is as follows. Inflammation in synovium 
and/or  joint  space:  0  =  no  inflammation,  +1  =  minimal,  +2  =  mild,   
+3 = moderate, +4 = severe; fibrosis (periarticular or pannus formation):   
+1 = minimal, +2 = mild, +3 = moderate, +4 = severe; percent PMNs:   
1 = <20%, 2 = 20–40%, 3 = 40–60%, 4 = >60%; articular cartilage damage 
(destruction/pitting): +1 = minimal, +2 = mild, +3 = moderate, +4 =   
severe; cortical bone erosions/periosteal bone or cartilage proliferation: 0 = 
normal bone, +1 = minimal erosions, +2 = mild erosions, +3 = moderate, 
+4 = severe.
Macrophage and osteoclast culture assays. Macrophage cultures were 
generated from C57BL/6 or B10.RIII mice. Bone marrow was extracted 
from the femurs and tibias of 8–12-wk-old week animals. Cells were cul-
tured for 1–5 d in basal macrophage growth medium, which is comprised of 
-Mem media (Invitrogen), supplemented with 10% heat-inactivated fetal 
bovine serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, 1 mM so-
dium pyruvate, 2 mM glutamine, and 50 ng/ml of recombinant MCSF 
(R&D Systems). Bone marrow–derived cells were cultured in various con-
ditions and stained with biotinylated anti–MDL-1 (clone DX192). Samples 
were analyzed by FACSCalibur and FlowJo software (BD).
Osteoclasts were differentiated from bone marrow cells after 3 d culture 
in basal macrophage medium. Adherent cells were plated at 1– 5 × 105 per 
ml in 6-well tissue culture plates and were treated with murine RANKL 
(10–50 ng/ml) and anti–MDL-1 or isotype control mAb at (10 µg/ml). 
Anti–MDL-1 activated cells were evaluated for osteoclast formation, gene 
expression, and TRAP staining (Acid phosphatase staining kit: Sigma) after 
6–8 d in culture.
Nuclear  NFATc1  quantification. NFATc1 is dephosphorylated upon 
activation by calcineurin in the cell cytoplasm and then translocated to the 
nucleus. To determine the ability agonist MDL-1 mAb to activate nuclear 
migration, 2 × 107 murine bone marrow cells were cultured in 10-mm 
dishes with 50 ng/ml of MCSF, 50 ng/ml of MCSF plus 30 ng/ml RANKL, 
and  either  10  µg/ml  of  IgG1  isotype  or  anti–MDL-1  agonist  antibody.   
Nuclear lysates were prepared from cells harvested at day 6 as described in 
Active Motif’s nuclear extract kit. Nuclear samples were quantified by Bradford 
protein determination using lysis buffer as the diluent. 1-µg protein samples 
were run in duplicate on the NFATc1 assay. Plates were coated with an im-
mobilized NFAT oligonucleotide consensus sequence (5-AGGAAA-3). 
The primary antibody specifically binds the accessible epitope on the 
NFATc1 protein. Secondary HRP-conjugated antibody allows colorimetric 
readout. Samples were visualized using SpectraMax (Molecular Devices) 
plate reader at 450 nm with a reference wavelength of 655. Samples were 
analyzed  using  SoftMax  pro  software  (Molecular  Devices),  and  nuclear   
MATERIALS AND METHODS
Reagents  and  antibodies.  MDL-1  (GenBank/EMBL/DDBJ  accession 
no.  BC112099).  Anti–mMDL-1  agonist  (clone:  DX163)  was  generated 
from rats using immunogenic fusion proteins consisting of the extracellular 
domain of the mouse MDL-1 gene, including the amino acid positions 26–
166 (GenBank/EMBL/DDBJ accession no. AF139769). Both anti–MDL-1 
mAbs are IgG1 isotype. Mouse MDL-1 fusion protein was generated as   
follows: extracellular (163 amino acids) portion of mouse MDL-1 (Gen-
Bank/EMBL/DDBJ accession no. AA186015) was ligated into a pCMV1 
expression  plasmid  containing  the  Fc  portion  of  mIgG2a  that  has  been   
mutated (L to E) for low FcRI binding properties. Protein was expressed in 
293 freestyle cells.
Acquisition of human tissue. Human synovial samples were obtained 
under informed consent from RA patients under a protocol approved by the 
Stanford University IRB and performed at the Stanford University Hospital. 
For the human anatomy panel, depending on the collection protocols estab-
lished at each site, tissues were acquired either under IRB-approved waiver 
of consent (NDRI and CHTN) or by informed consent (PAH, Zoion,   
Ardais, and AGF). All samples have been rendered anonymous, so investiga-
tors have no ability to identify the patients. Normal human tissues were ob-
tained from patients undergoing routine surgery (multiple tissue, NDRI; 
stomach, Ardais Corporation; and colon, Cooperative Human Tissue Net-
work), from short hour autopsy (≤ 5 h, multiple tissues; Zoion Diagnostics), 
and from transplant donors (lung, Anatomical Gift Foundation, Hanover, 
MD). All surgical samples were frozen as quickly as possible, typically within 
an hour of excision. The majority of samples were accompanied by demo-
graphic information and pathology reports.
Immunostaining  of  MDL-1.  All  human  tissue  experiments  were   
performed in accordance with animal care and use committee–approved 
protocols. Immunohistochemistry was performed on frozen OCT embed-
ded RA and OA synovia. 8-µm sections were fixed in acetone-methanol-
hydrogen peroxide, and blocked with FCS-BSA-rat serum. Tissues were 
further blocked with avidin (Vector Laboratories) for 15 min and biotin 
(Vector Laboratories) for another 15 min. Sections were stained with anti–
hMDL-1 mAb (clone DX245), anti-hCD68, or isotype control rat anti-
bodies for 3 h and fixed with 1% paraformaldehyde. Tissues were washed 
and incubated with biotinylated rabbit anti–rat antibodies for 1 h, and Vec-
tastain ABC elite horseradish peroxidase (HRP) complex for 40 min. Cell 
surface  markers  (MDL-1  and  CD68)  were  visualized  with  Nova  Red   
(Vector Laboratories) substrate and counterstained with methyl green.
Induction of CAIA and CIA. All animal experiments were performed in 
accordance with institutional animal care and use committe–approved pro-
tocols. Arthritis was induced in 8–16-wk-old (age-matched for a given 
study) male B10.RIII (Jackson ImmunoResearch Laboratories) with an arth-
ritogenic anti-type II collagen mAb cocktail purchased from Chemicon In-
ternational or Chondrex. B10RIII mice received 1–1.5 mg of anti-CII mAb 
cocktail i.v. on day 0. Mice were then treated s.c. with 0.5–1 mg of anti–
MDL-1 or IgG1 isotype control. Alternatively, mice were treated s.c. with 
0.5 mg of MDL-1 Ig-fusion protein or Ig-fusion control protein at day 0, 2, 
and 4. C57BL/6 mice received 5 mg arthrogen on day 0 and 10–50 µg of   
E. coli–derived LPS on day 2. Mice were monitored daily for foot pad swell-
ing through day 11 or up to day 21.
12-16-wk-old B10RIII mice were immunized with 1 mg of bovine 
type-II collagen in a complete Freund’s adjuvant (Difco) emulsion contain-
ing 2 mg/ml H37RA (Chondrex). Initial incidence of disease occurred at 
day 18 in 33–50% of all mice. On day 18, mice were given a single dose of 
0.5 mg of anti–MDL-1 agonist or IgG1 isotype control. MDL-1 Ig-fusion 
protein (antagonist) or its corresponding mutant mouse Ig-fusion protein 
control were dosed every other day (starting on day 18) for a total of 6 doses. 
Mice were monitored for paw swelling through day 35. Paw swelling was 
measured daily after induction of arthritis. The severity of the disease was 
graded on a 0–3 scale per paw as follows: 0, normal; 1, swelling of one digit; 588 MDL-1 regulation of joint inflammation | Joyce-Shaikh et al.
volume (BV). Total BV measurements in the metatarsal phalangeal joints 
encompass regions of trabecular and cortical bone. Mean cortical thickness 
analyses were performed using MicroView 2.2 software package to measure 
metatarsal phalangeal joint.
Peripheral  blood  analysis.  Murine  blood  was  harvested  by  cardiac   
puncture and collected in EDTA tubes (Terumo Medical Corp.) Blood 
samples were processed with Advia 120 Automated Hematology Analyzer. 
Percentage of monocytes, neutrophils, and high peroxidize positive (per-
centage of HPX) cells were compared with naive control mice.
Online  supplemental  material.  Fig.  S1  demonstrates  a  mast  cell  de-
granulation assay detecting the specific agonist activity of MDL-1. Fig. S2 
shows micrographs of human RA synovial tissue stained for myeloid cell 
markers and MDL-1. Fig. S3 shows murine bone marrow and peripheral 
blood have increased numbers of MDL-1 positive cells after CAIA induc-
tion. Fig. S4 confirms depletion of a CD11b+ subset from blood after treat-
ment with anti-GR1 antibody in CAIA. Fig. S5 shows collagen induced 
arthritis is exacerbated by agonist MDL-1 antibody treatment. Fig. S6   
depicts the Mdl1/ mouse gene targeting strategy. Fig. S7 shows the nor-
malized  gene  expression  values  for  WT,  Mdl1/,  and  Dap12/  mice 
in CAIA model. Fig. S8 shows H&E staining from hind paws of mice in 
CAIA model where mice were treated with MDL-1 agonist and antago-
nist reagents. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20090516/DC1.
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